The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

Cleland, John GF, Prof ; Teerlink, John R, Prof ; Senior, Roxy, Prof ; Nifontov, Evgeny M, Prof ; Mc Murray, John JV, Prof ; Lang, Chim C, Prof ; Tsyrlin, Vitaly A, Prof ; Greenberg, Barry H, Prof ; Mayet, Jamil, MD ; Francis, Darrel P, MD ; Shaburishvili, Tamaz, MD ; Monaghan, Mark, PhD ; Saltzberg, Mitchell, MD ; Neyses, Ludwig, Prof ; Wasserman, Scott M, MD ; Lee, Jacqueline H ; Saikali, Khalil G, PhD ; Clarke, Cyril P, MBBS ; Goldman, Jonathan H, MD ; Wolff, Andrew A, MD ; Malik, Fady I, MD

The Lancet (British edition), 2011-08, Vol.378 (9792), p.676-683 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível